Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
Hematology
How do you adjust tyrosine kinase inhibitors, if at all, in a patient with new vascular events in a patient with CML-accelerated phase?
For instance, such as ischemia in intestinal mucosal tissue and MI
Related Questions
Would you use a matched sibling donor with a germline heterozygous BRCA1 mutation for stem cell transplant?
Do you prefer quizartinib over midostaurin with chemotherapy induction for FLT3-ITD mutated AML given the results of QUANTUM-FIRST and preclinical advantages over other FLT3 inhibitors?
For AML patients, when do you stop antiinfective agents?
How would you treat an LGL leukemia patient who has been refractory to treatments with cyclosporine, MTX, and cyclophosphamide?
What is your current approach to maintenance therapy in FLT3-mutant AML post allogeneic HCT?
Do complex cytogenetics have any therapeutic or prognostic relevance in CLL?
Is it possible to give Inotuzumab ozogamicin in the front line setting for an older patient with Ph- Pre-B-ALL?
How long do you continue ATRA during induction in high risk acute promyelocytic leukemia?
Would you offer intensive CNS prophylaxis to Ph negative B-ALL patients who have possible mandibular nerve involvement on MRI face?
What are your top takeaways in Hematologic Malignancies from ASCO 2023?